Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30730600 | 0.89 | PKM (0.42) | LMNAMEN1RAB9AKMT2APKM | |
| SCHEMBL30730498 | 0.83 | LMNA (0.39) | LMNAMEN1RAB9AKMT2APKM | |
| SCHEMBL30730533 | 0.82 | EPHX2 (0.48) | LMNAMEN1RAB9AKMT2APKM | |
| SCHEMBL30730608 | 0.81 | HSD11B1 (0.44) | LMNAPKMALOX15TSHRMAPK1 | |
| SCHEMBL30730447 | 0.81 | LMNA (0.42) | LMNAMEN1RAB9AKMT2APKM | |
| SCHEMBL30730450 | 0.80 | LMNA (0.39) | LMNAMEN1RAB9AKMT2APKM | |
| SCHEMBL30730506 | 0.80 | HSD11B1 (0.46) | LMNAPKMALOX15TSHRMAPK1 | |
| SCHEMBL32676926 | 0.80 | LMNA (0.39) | LMNAMEN1RAB9AKMT2APKM | |
| SCHEMBL30730441 | 0.79 | LMNA (0.40) | LMNAMEN1RAB9AKMT2APKM | |
| SCHEMBL30730516 | 0.79 | LMNA (0.40) | LMNAMEN1RAB9AKMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | SCRIPPS RESEARCH INST (US) | 2026-02-19 | — | — | US | claimed |
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | SCRIPPS RESEARCH INST (US) | 2026-02-19 | — | — | US | disclosed |
| WO-2024030121-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | FNTB, PDE7A, TBL3 | LMNA 1838/4885MEN1 3684/4885RAB9A 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.